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Introduction: Smoking is a main risk factor for morbidity and mortality in people living with 
human immunodeficiency virus (PLHIV), but its potential association with renal impairment 
remains to be established.
Methods: We did a nationwide population-based cohort study in Danish PLHIV to evaluate 
the association between smoking status and 1) overall renal function and risk of chronic kidney 
disease (CKD), 2) risk of any renal replacement therapy (aRRT), and 3) mortality following 
aRRT. We calculated estimated creatinine clearance using the Cockcroft–Gault equation (CG-
CrCl), and evaluated renal function graphically. We calculated cumulative incidence of CKD 
(defined as two consecutive CG-CrCls of #60 mL/min, $3 months apart) and aRRT and used 
Cox regression models to calculate incidence rate ratios (IRRs) for risk of CKD, aRRT, and 
mortality rate ratios (MRRs) following aRRT.
Results: From the Danish HIV Cohort Study, we identified 1,475 never smokers, 768 previ-
ous smokers, and 2,272 current smokers. During study period, we observed no association of 
smoking status with overall renal function. Previous and current smoking was not associated 
with increased risk of CKD (adjusted IRR: 1.1, 95% confidence interval [CI]: 0.7–1.7; adjusted 
IRR: 1.3, 95% CI: 0.9–1.8) or aRRT (adjusted IRR: 0.8, 95% CI: 0.4–1.7; adjusted IRR: 0.9, 
95% CI: 0.5–1.7). Mortality following aRRT was high in PLHIV and increased in smokers vs 
never smokers (adjusted MRR: 3.8, 95% CI: 1.3–11.2).
Conclusion: In Danish PLHIV, we observed no strong association between smoking status 
and renal function, risk of CKD, or risk of aRRT, but mortality was increased in smokers fol-
lowing aRRT.
Keywords: chronic kidney disease, renal replacement therapy, mortality, creatinine clearance, 
incidence rate ratio, mortality rate ratio
Introduction
Since the introduction of highly active antiretroviral therapy (HAART), the natural 
course of human immunodeficiency virus (HIV) infection has changed dramatically 
from being invariably fatal to a chronic disease with an overall favorable prognosis. 
However, people living with HIV (PLHIV) still suffer from a significantly increased 
all-cause mortality compared to the background population.1
PLHIV have a faster decline in renal function and a higher risk of any renal replace-
ment therapy (aRRT) and end-stage renal disease (ESRD) compared to the background 
population, but the mechanisms of the deterioration in renal function are not fully 
understood.2–4 Exposure to antiretrovirals (eg, tenofovir and atazanavir) has been 
associated with deterioration of renal function.5–7 Furthermore, HIV has been found to 
replicate in other cells than CD4 cells, for example, renal epithelial cells.8 This seems 
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to be directly associated with HIV-associated nephropathy 
seen mainly in PLHIV of black-African origin.9
Recent studies indicate that lifestyle-related factors (eg, 
smoking and other substance abuse) are more important 
than HIV-related factors as predictors of long-term survival 
among PLHIV.10–13
We hypothesized that smoking is a risk factor for decline 
in renal function, chronic kidney disease (CKD), aRRT, and 
death following aRRT in PLHIV. We therefore assessed the 
association between smoking status and 1) renal function and 
CKD, 2) risk of aRRT, and 3) mortality following aRRT.
Methods
study design
We performed a population-based cohort study divided into 
three parts in which we estimated the association of smoking 
with the following: 1) overall renal function, evaluated by esti-
mated  creatinine clearance calculated with the Cockcroft–Gault 
 equation (CG-CrCl), and the risk of CKD (as defined in the sec-
tion Categorization of smoking, renal function, CKD and CD4 
cell count), 2) risk of aRRT, and 3) mortality following aRRT.
setting
Denmark had a population of approximately 5.5 million people, 
and an estimated HIV prevalence of 0.1% among adults in 
December 2013.14 PLHIV are treated in eight specialized HIV 
care centers and are seen on an outpatient basis at intended inter-
vals of 12–24 weeks. Antiretroviral treatment is provided free 
of charge. Management of PLHIV is well organized, and rates 
of treatment failure and loss to follow-up are low.15,16
Data sources – registries
The unique ten-digit personal identification number assigned 
to all Danish residents at birth or immigration was used to 
track individuals in the following registries.
The Danish HIV Cohort Study (DHCS) is a prospective 
study of all PLHIV, 16 years or older at diagnosis, treated 
at Danish HIV centers after January 1, 1995. Individuals 
are consecutively enrolled, and data are annually updated 
and include demographics, date of HIV diagnosis, acquired 
immunodeficiency syndrome (AIDS)-defining events, and 
antiretroviral treatment. CD4 cell counts and viral loads are 
extracted electronically from laboratory data files. The study 
is described in detail elsewhere.17,18
Data on vital status, residency, and migration were 
extracted from the Danish Civil Registration System (DCRS) 
which was established in 1968 and stores information on all 
Danish residents.19
From the Danish National Hospital Registry (DNHR), we 
identified dialysis according to the International  Classification 
of Diseases tenth revision (ICD-10) as BJFD.xx, ZZ43.40-
ZZ43.50 or International Classification of  Diseases eighth 
revision (ICD-8) as 92390, 94399, 94340, and 94350. 
aRRT was defined as the first date of dialysis. With this 
 definition of aRRT, we include both patients with chronic 
renal replacement therapy (cRRT) and patients who develop 
acute renal failure and require acute dialysis. We defined 
cRRT as dialysis for $3 months. Furthermore, we identified 
individuals with diagnoses of hypertension (ICD-10: DI10-
DI15.9 and ICD-8: 40009-41499) and diagnoses of diabetes 
(ICD-10: DE10.0-DE14.9 and ICD-8: 24900-25009). DNHR 
is described in detail elsewhere.20
Categorization of smoking, renal function, 
CKD, and CD4 cell count
Data on smoking were obtained by interview. Individuals were 
categorized as smokers if they smoked any type of tobacco 
at least once a week or if they categorized themselves as 
smokers. Individuals were categorized as never,  previous, and 
current smokers according to their status at study  inclusion 
and did not change category during study period.
Serum creatinines were extracted from electronic labora-
tory databases and included all serum creatinines measured 
in the period 1995–2013 during inpatient admittances and 
outpatient planned controls. All serum creatinines were 
standardized according to the Jaffe method as described by 
the local laboratories. As an estimate of glomerular filtration 
rate (GFR), we calculated CG-CrCl without correction of 
body surface area.21,22
 
CG CrCl (140 age) weight (in kg)
1.04
serum creatinine in
mo
− −
− µ
= ×
×
l
L
(if female)



  
(1)
 CG CrCl (140 age) weight (in kg)
1.23
serum c nine in
mo
− −
− µ
= ×
×
reati
l
L
(if male)




To calculate CG-CrCl, the age at the date of the actual 
serum creatinine measurement and the weight closest to that 
date were used. Thus, an individual with only one weight 
available was assumed to have the same weight throughout 
the entire study period.
In sensitivity analyses, we used the CKD epidemiological 
collaboration (CKD-EPI) equation to estimate GFR.23
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where serum creatinine is measured in µmol/L, κ is 61.9 
for females and 79.6 for males, α is -0.329 for females 
and -0.411 for males, min indicates the minimum of serum 
creatinine/κ or 1, and max indicates the maximum of serum 
creatinine/κ or 1. CKD was defined as two consecutive 
 CG-CrCls of #60 mL/min, $3 months apart. The date of the 
second CG-CrCl measurement was defined as date of CKD. 
CD4 cell count and CG-CrCl at study inclusion were defined 
as the CD4 cell count and the CG-CrCl closest to and within 
2 years before and 6 months after study inclusion.
study population
We included all PLHIV who 1) had available data on smoking 
status, 2) had a unique Danish person identification number, 
3) were 16 years or older at study inclusion, 4) were alive 
and living in Denmark at study inclusion, and 5) did not 
have aRRT at or prior to study inclusion. This population 
was included in part 2.
In part 1, the following inclusion criteria were added. 
Individuals who 1) had at least three CG-CrCls available 
during the study period, 2) had data on weight available, and 
3) did not have CKD prior to study inclusion, for analyses 
evaluating risk of CKD.
In part 3, all patients from part 2 with aRRT were 
included.
study design
Part 1 – smoking, renal function, and CKD
For the assessment of overall renal function over time, time 
was calculated from January 1, 1995, date of HIV diagnosis, 
date of first available data on smoking, first available CG-
CrCl or date of immigration whichever occurred last to date 
of aRRT, last available CG-CrCl, loss to follow-up, emi-
gration, death, or 10 years after study inclusion, whichever 
occurred first. Observation time was divided into intervals 
of 3 months starting from study inclusion. If an individual 
had more than one CG-CrCl within a 3-month interval, 
median CG-CrCl was used. If no CG-CrCl was recorded 
within a 3-month interval, we calculated the CG-CrCl as a 
weighted mean of the two nearest CG-CrCl measurements, 
thereby assuming linearity between the two measurements. In 
consequence, all individuals contributed with a CG-CrCl in 
every 3-month time interval. We then graphically  evaluated 
median CG-CrCl according to smoking status for every 
3-month interval. When we evaluated risk of CKD, time was 
calculated from January 1, 1995, date of HIV diagnosis, date 
of first available data on smoking, first available CG-CrCl 
or date of immigration whichever occurred last to date of 
CKD, last available CG-CrCl, loss to follow-up,  emigration, 
death, or 10 years after study inclusion, whichever occurred 
first. Outcome was time to CKD. We calculated cumulative 
incidence with death, emigration, and loss to follow-up 
as competing risks to estimate cumulative risk of CKD. 
We calculated incidence rates (IRs) and used Cox regres-
sion to calculate incidence rate ratios (IRRs) of CKD. The 
 following covariates were included in the final model: gender 
(male vs female), race (Caucasian, African, or other), route 
of  infection (men who have sex with men, intravenous drug 
use [IDU], heterosexually infected, or other), CD4 cell count 
(,200 cells/µL vs $200 cells/µL) at study inclusion, and 
CG-CrCl (,90 mL/min vs $90 mL/min) at study inclusion. 
The following covariates were included as time-updated 
variables: age (5-year intervals), HAART exposure (yes/no), 
tenofovir exposure (yes/no), diabetes (yes/no), hypertension 
(yes/no), and AIDS (yes/no). In sensitivity analyses, we 
estimated GFR with the CKD-EPI equation.
Part 2 – smoking and arrT
Time was calculated from January 1, 1995, date of HIV 
diagnosis, date of first available data on smoking or date 
of immigration whichever occurred last to date of aRRT, 
loss to follow-up, emigration, death, or 10 years after study 
inclusion, whichever occurred first. Outcome was time to 
aRRT, as defined earlier.
We calculated cumulative incidence with death, emigra-
tion, and loss to follow-up as competing risks to estimate 
cumulative risk of aRRT. We calculated IRs and used 
Cox regression to calculate IRR of aRRT. The  following 
 covariates were included in the final model: gender (male vs 
female), race (Caucasian, African, or other), route of  infection 
(men who have sex with men, IDU,  heterosexually infected, 
or other), and CD4 cell count (,200 cells/µL vs $200 
cells/µL) at study inclusion. The following  covariates 
were included as time-updated  variables: age (5-year 
 intervals), HAART exposure (yes/no), tenofovir exposure 
(yes/no), diabetes (yes/no), hypertension (yes/no), and 
AIDS (yes/no). To test for effect modification, we stratified 
the  analyses on gender, route of infection, race, and CD4 
cell count at study  inclusion. We did sensitivity analyses 
excluding IDUs from the analyses and analyses excluding 
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individuals of non-Danish origin. Furthermore, we analyzed 
the risk of cRRT according to smoking status.
Part 3 – smoking and mortality following arrT
Time was calculated from aRRT to death, emigration, loss 
to follow-up, December 31, 2013, or 56 days after study 
inclusion whichever came first. Outcome was time from 
aRRT to death, and Cox regression analyses were used to 
estimate mortality rate ratios (MRRs). We included age at 
inclusion and gender as covariates in the model. We did not 
include comorbidities in the adjusted analyses as these cova-
riates most likely are facilitators and not confounders of the 
increased mortality in smokers. Kaplan–Meier survival tables 
were used to construct survival curves following aRRT. In 
secondary analyses, IDUs were excluded from the analyses. 
Furthermore, we did a sensitivity analyses only including 
individuals of Danish origin.
For part 1 of the study, we did sensitivity analyses using 
the CKD-EPI equation to estimate GFR.23 We used the 
tests of the nonzero slope to test for proportional hazard 
 assumptions. The study was approved by the Danish Data 
Protection Agency (journal no 2008-41-1781). Stata software, 
Version 11.0 (StataCorp, College Station, TX, USA) and R 
version 3.1.3 were used to perform statistical analyses.
Results
Overall
On December 31, 2013, a total of 6,239 PLHIV were regis-
tered in DHCS. Approximately 1,707 had missing data on 
smoking, and 17 had aRRT before inclusion (five patients 
[0.3%] among never smokers, three patients [0.4%] among 
previous smokers, and nine patients [0.4%] among current 
smokers) leaving 4,515 PLHIV in the study with a total of 
29,196 person years of follow-up (PYFU).
Approximately 1,475 (32.7%) PLHIV were categorized as 
never smokers, 768 (17.0%) as previous smokers, and 2,272 
(50.3%) as current smokers. Median age among previous 
smokers (39.7 years, interquartile range [IQR]: 32.3–48.3) 
was higher than among never and current smokers (35.2 years, 
IQR: 29.5–43.9; 36.4 years, IQR: 30.4–43.7). Number of 
deaths during study period was greater among current smokers 
than among never and previous smokers. Characteristics of 
the study population are summarized in Table 1.
Part 1 – smoking, renal function,  
and CKD
In part 1, 3,142 PLHIV with at least three CG-CrCls 
 available were included. No association between smoking 
status and median CG-CrCl was observed (Figure 1A). 
When  modeling risk of CKD, we excluded 128 individuals 
with CKD prior to study inclusion leaving 3,014 PLHIV 
with a total of 18,131 PYFU. We identified 180 cases 
of CKD, 47 among never smokers, 43 among previous 
smokers, and 90 among current smokers. IRs (per 10,000 
PYFU) of CKD were 83.2 (95% confidence interval [CI]: 
62.5–110.8) for never smokers, 132.7 (95% CI: 98.4–178.9) 
for  previous smokers, and 97.4 (95% CI: 79.2–119.7) for 
current smokers. In the unadjusted model, previous  smoking 
was associated with increased risk of CKD compared to 
never smoking (IRR: 1.6, 95% CI: 1.1–2.4), whereas  current 
smoking was not associated with risk of CKD (IRR: 1.2, 
95% CI: 0.8–1.6). In the adjusted models, this associa-
tion was not present (IRR: 1.1, 95% CI: 0.7–1.7 and IRR: 
1.3, 95% CI: 0.9–1.8) for previous smokers and current 
smokers (Figure 1B and Table 2), with differences in age 
Table 1 Characteristics of study population
Smoking status
Never Previous Current
individuals 1,475 (32.7) 768 (17.0) 2,272 (50.3)
Follow-up (years) 9,694 5,000 14,502
loss to follow-up 2 (0.1) 3 (0.4) 5 (0.2)
Emigrated 81 (4.0) 30 (3.9) 75 (3.3)
Deaths 75 (5.1) 81 (10.5) 411 (18.1)
age at study  
inclusion (yearsa)
35.2 (29.5–43.9) 39.7 (32.3–48.3) 36.5 (30.4–43.7)
Male 912 (61.8) 617 (80.6) 1,840 (80.9)
raceb
 Caucasian 919 (62.2) 628 (81.9) 1,983 (87.3)
 african 406 (27.5) 82 (10.7) 129 (5.7)
 Others/unknown 150 (10.2) 58 (7.4) 160 (7.0)
route of infectionb
 MsM 596 (40.4) 404 (52.6) 1,114 (49.0)
 IDU 12 (0.8) 37 (4.7) 316 (14.0)
 heterosexually 769 (52.0) 277 (36.1) 736 (32.3)
 Others 98 (6.7) 52 (6.6) 106 (4.7)
Comorbidities
 Diabetes 35 (2.4) 19 (2.5) 56 (2.5)
 hypertension 98 (6.6) 46 (6.1) 99 (4.4)
 AIDS 38 (2.6) 40 (5.2) 107 (4.7)
CD4 cell count  
(cells/µL)a,b
435 (291–600) 410 (256–600) 445 (273–650)
Weight (kg)a,b 74.5 (65.0–84.0) 75.0 (67.0–84.2) 71.2 (63.4–80.0)
Missing 491 (33.2) 238 (31.0) 644 (28.3)
Cg-CrCl  
(mL/min)a,b
102 (88–120) 101 (87–119) 103 (87–121)
Missing Cg-CrCl  
at study inclusion
491 (33.2) 238 (31.0) 644 (28.3)
Notes: Data are numbers (%) unless otherwise specified; amedian (interquartile 
range); bat study inclusion.
Abbreviations: MSM, men who have sex with men; IDU, intravenous drug user; 
AIDS, acquired immunodeficiency syndrome; CG-CrCl, estimated creatinine 
clearance calculated with the Cockcroft–Gault equation.
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Figure 1 Estimated creatinine clearance and risk of chronic kidney disease stratified on smoking status.
Notes: (A) 25%, median, and 75% percentiles of estimated creatinine clearance stratified on smoking status. We used the Cockcroft–Gault equation to calculate estimated 
creatinine clearance (displayed as mL/min) as estimate of glomerular filtration rate. We divided time from study inclusion until end of follow-up in 3-month intervals. In 
each interval, all participants contributed with one CG-CrCl. The CG-CrCl in a time interval was either the median of all CG-CrCls in that time interval. If no CG-CrCl 
was available in a 3-month time interval, the CG-CrCl was calculated as the weighted mean of the CG-CrCl measurements determined before and after the actual 3-month 
period. At study inclusion, there were 984 never smokers, 530 previous smokers, and 1,628 current smokers. At 10 years of follow-up, 110 never smokers, 98 previous 
smokers, and 170 current smokers were still under follow-up. (B) Risk of chronic kidney disease stratified on smoking status. Definition of chronic kidney disease: two 
consecutive Cg-CrCls of #60 ml/min $3 months apart.
Abbreviation: CG-CrCl, estimated creatinine clearance calculated with the Cockcroft–Gault equation.
between never smokers and previous smokers explaining 
most of the risk difference observed between these groups 
(adjusting for only age – IRR: 1.2, 95% CI: 0.8–1.8 and 
IRR: 1.3, 95% CI: 0.9–1.9 for previous and current smok-
ers, respectively). As seen in Figure 1B, previous smokers 
seemed to have increased risk of CKD from 5 years after 
study  inclusion. We therefore performed a Cox regression 
analysis in which time was split at 5 years after study 
 inclusion. In this  analysis, adjusted IRR for previous 
 smokers vs never smokers was 3.4 (95% CI: 1.3–8.7). When 
we used the CKD-EPI equation to estimate GFR, it did not 
change the results substantially (IRR: 1.1, 95% CI: 0.7–1.6 
and IRR: 0.8, 95% CI: 0.5–1.2 for previous smokers and 
current smokers, respectively).
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Part 2 – smoking and arrT
In this part, we included the complete cohort of 4,515 
PLHIV with known smoking status. We identified a total of 
62 cases of aRRT (20, 11, and 31 among never, previous, 
and current smokers). IRs (per 10,000 PYFU) of aRRT were 
20.6 (95% CI: 13.3–31.9) for never smokers, 22.0 (95% 
CI: 12.2–39.7) for previous smokers, and 21.4 (95% CI: 
15.0–30.4) for  current smokers. The risk of aRRT in previous 
and current smokers did not differ substantially from that of 
never  smokers (Figure 2 and Table 2). Excluding IDUs or 
individuals of non-Danish origin only changed the estimates 
marginally (results not shown). Only 17 patients (nine never 
smokers, two previous smokers, and six current smokers) 
were categorized with cRRT in the study period, and did 
not allow us to make robust conclusions about association 
of smoking and risk of cRRT.
Part 3 – smoking and mortality  
following arrT
In this part of the study, we included the 62 individuals from 
part 2 who initiated aRRT. They had a total of 344 person 
days of follow-up (PDFU). During the observation time, 
26 deaths were recorded, and mortality rates (MRs per 
1,000 PDFU) were 29.0 (95% CI: 10.9–77.3), 65.3 (95% 
CI: 23.0–163.0), and 128.0 (95% CI: 80.6–203.0) for never 
 smokers,  previous smokers, and current  smokers,  respectively. 
The  unadjusted MRRs were 2.0 (95% CI: 0.5–8.2) and 3.9 
(95% CI: 1.30–11.5) for previous  smokers and current 
smokers, respectively, compared to never smokers (Fig-
ure 3). When adjusting for gender  and age at study inclu-
sion, the MRRs were 1.9 (95% CI: 0.5–7.8) and 3.8 (95% 
CI: 1.3–11.2) for previous and current smokers, respectively, 
compared to never smokers. Excluding IDUs or individuals 
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Figure 3 Mortality following any renal replacement therapy stratified on smoking 
status.
Table 2 Risk of CKD and aRRT
Smoking statusa Individuals with CKD  
during follow-up
IR per 10,000  
PYFU (95% CI)
IRR (95% CI)
Unadjusted Adjusted
Risk of CKDb
 never 47 83.2 (62.5–110.8) ref ref
 Previous 43 132.7 (98.4–178.9) 1.6 (1.1–2.4) 1.1 (0.7–1.7)
 Current 90 97.4 (79.2–119.7) 1.2 (0.8–1.6) 1.3 (0.9–1.8)
risk of arrT
 never 20 20.6 (13.3–31.9) ref ref
 Previous 11 22.0 (12.2–39.7) 1.1 (0.5–2.2) 0.8 (0.4–1.7)
 Current 31 21.4 (15.0–30.4) 1.0 (0.6–1.8) 0.9 (0.5–1.7)
Notes: aAt study inclusion; bdefinition of CKD: two consecutive CG-CrCls of #60 ml/min $3 months apart. For CKD: adjusted for age, gender, HAART exposure, tenofovir 
exposure, race, route of infection, comorbidities (diabetes, hypertension, and AIDS), included as time-updated variables, CD4 cell count, and CG-CrCl at study inclusion. For 
aRRT: adjusted for age, gender, HAART exposure, tenofovir exposure, race, route of infection, comorbidities (diabetes, hypertension, and AIDS), included as time-updated 
variables and CD4 cell count.
Abbreviations: CKD, chronic kidney disease; aRRT, any renal replacement therapy; IR, incidence rate; PYFU, person years of follow-up; CI, confidence interval; IRR, 
incidence rate ratio; CG-CrCl, estimated creatinine clearance calculated with the Cockcroft–Gault equation; HAART, highly active antiretroviral treatment; AIDS, acquired 
immunodeficiency syndrome; Ref, reference.
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Figure 2 Risk of any renal replacement therapy stratified on smoking status.
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of non-Danish origin only changed the estimates marginally 
(results not shown).
Discussion
In this Danish nationwide population-based cohort study, 
we found no evidence that smoking status was associated 
with decline in renal function, risk of CKD, or risk of aRRT. 
 Mortality was high following aRRT, and substantially 
increased in smokers.
GFR in smokers has not convincingly been shown to be 
decreased compared to nonsmokers. A large cross-sectional 
study from France which included 28,409 individuals from 
the background population found that smoking was associ-
ated with a slightly increased CG-CrCl and albuminuria.24 
Increased GFR and albuminuria in smokers simultaneously 
have led to the hypothesis that smoking is associated with 
glomerular hyperfiltration, a phenomenon also described in 
other disease entities such as diabetes.25,26 Thus, glomerular 
hyperfiltration could be part of the pathogenesis leading to 
proteinuria in smokers. It could also hide a potential harmful 
effect of smoking on renal function. Another explanation for 
an elevated CG-CrCl in smokers could be that smokers tend 
to have more sedentary activities compared to nonsmokers,27 
which results in lower muscle mass and thereby lower 
serum creatinine and higher CG-CrCl. To compensate for 
differences in muscle mass, we chose to use the CG-CrCl 
as an estimate of GFR. However, a change in body weight 
is not solely explained by a change in total muscle mass, 
and hence, this equation only partly adjusts for differences 
in muscle mass.
It is controversial whether smoking increases the risk of 
renal insufficiency in the general population.28 Some studies 
have evaluated the association between smoking and aRRT 
or ESRD in the general population. Haroun et al found that 
smoking was associated with ESRD or CKD as cause of 
death in both men and women with adjusted IRR of 2.4 (95% 
CI: 1.4–4.0) and 2.9 (95% CI: 1.7–5.0) for men and women, 
respectively. However, this effect was primarily present after 
the age of 60.29 In a study including more than 300,000 indi-
viduals from the background population, Klag et al concluded 
that smoking was significantly associated with ESRD, but the 
magnitude of the effect of smoking was not reported.30 The 
populations in the above-mentioned studies were older than 
the population in our study, which may explain some of the 
discrepancies as only 4% of the population in our study were 
older than 60 years of age at study inclusion. We observed 
a trend toward increased risk of CKD in previous smokers 
from 5 years after study inclusion. We presume that this is a 
chance finding but cannot exclude that the morbidity, which 
prompted smoking cessation, later leads to deteriorating 
renal function.
Only a few studies have evaluated smoking as a risk  factor 
for renal disease in PLHIV. Ryom et al included  smoking as a 
covariate when evaluating HAART exposure as a risk  factor for 
advanced CKD or ESRD in the D:A:D study. They found 
that smoking was associated with a statistically significant 
increased risk of advanced CKD/ESRD (IRR  approximately 
1.9).31 In contrast to our study, the D:A:D study included 
patients with unknown smoking status at enrollment and was 
not designed to show effects of smoking on renal  function. 
Furthermore, their population was slightly older than ours. 
As discussed earlier, one study has indicated that the effect of 
smoking on the risk of ESRD primarily affects people aged 60 
or older, and hence, a potential harmful effect of  smoking on 
renal function may be observed in our population as it grows 
older.29 We have shown that the mortality is higher among 
smokers than never smokers and previous smokers following 
aRRT. One could speculate that the reporting of aRRT may be 
more likely to take place if a patient dies. This could bias the 
results toward aRRT being associated with  smoking. The reg-
istration of dialysis in DNHR is coupled to the reimbursement 
system, and the hospital is only economically compensated if 
the correct diagnosis is registered in DNHR. We presume that 
this leads to a high and accurate registration of dialysis, and 
represents a significant difference from other studies evaluating 
dialysis as an outcome.32,33
Following aRRT, the mortality is increased in smokers 
compared to never smokers and previous smokers. Increased 
mortality in smokers while receiving renal replacement 
therapy is well established. In a large meta-analysis of 
ESRD patients performed in 2011, Liebman et al found a 
hazard ratio of 1.65 of death among smokers compared to 
nonsmokers.34 This is comparable to the estimates in our 
study. However, MRs in the present study are much higher 
than in previous studies. Our definition of aRRT results in 
an overrepresentation of patients on acute dialysis, com-
pared to patients on cRRT. Acute dialysis most often occurs 
with severe acute illnesses such as septic shock with a high 
mortality, which is the probable explanation for high MRs 
in our study.
Major strengths of the study are the following: 1) a 
population-based, nationwide design; 2) the use of DCRS, 
which assigns a personal identification number to all Danish 
citizens; 3) the well-organized structure of Danish national 
registers which allowed us to use well-validated data of high 
quality on vital status; and 4) the use of another  well-validated 
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Danish database the DNHR which enabled us to extract 
robust data on study outcomes.20
There are some limitations of the study: 1) We did not 
have access to data on CG-CrCl or aRRT in Danish individu-
als from the background population with known smoking 
status. 2) Smoking status was only available for about three 
quarters of Danish PLHIV. 3) Serum creatinine was measured 
by different testing methods over the 18-year study period, 
and we therefore cannot exclude some intra- and interlabora-
tory variation.35 In contrast to previous studies, we corrected 
for the varying testing methods as suggested by the local 
laboratories. 4) Our study period started from January 1, 
1995, and standardization of serum creatinine measurements 
was implemented in Denmark around 2004, and hence, a 
substantial part of the serum creatinine measurements has not 
been subject to standardization. 5) We chose to use CG-CrCl 
as an estimate of GFR, since a large number of PLHIV gain 
weight while recovering from their infection upon commenc-
ing HAART. This may introduce a bias as some patients did 
not have a specific weight available for each serum creati-
nine measurement. However, a sensitivity analysis using the 
CKD-EPI equation instead of the Cockcroft–Gault equation 
gave comparable results. 6) We did not have access to data 
on proteinuria or albuminuria, and hence, we were not able 
to test for association between smoking and proteinuria/
albuminuria. 7) Our definition of aRRT included both patients 
with ESRD on cRRT and patients on acute dialysis. However, 
IRR of CKD in the present study showed results that only 
differed marginally from the IRR of aRRT. We therefore 
believe that our results are rather robust.
We conclude that in Danish PLHIV, the overall renal 
function, the risk of CKD, or the risk of aRRT is not substan-
tially associated with smoking status, but smoking increases 
mortality following aRRT.
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